Orphan Europe

Recordati Rare Diseases, formerly known as Orphan Europe, is a specialized pharmaceutical company focused on the development and commercialization of orphan drugs for rare and ultra-rare diseases. Founded in 1990 and acquired by the Recordati Group in 2007, the company has established itself as a leader in metabolic disorders, endocrinology, and rare oncology. Its portfolio includes essential treatments such as Carbaglu for hyperammonemia, Cystadrops for cystinosis, and Isturisa for Cushing's syndrome. The company operates a global network with a strong emphasis on patient-centric support and specialized distribution to ensure access to life-saving therapies in underserved medical areas. Headquartered in France, it serves as the dedicated rare disease business unit for the broader Recordati Group.